A duo of experts from CureDuchenne discussed how the inclusion of Duchenne muscular dystrophy on the Recommended Uniform Screening Panel can enable earlier diagnosis and inform decision-making in a rapidly evolving therapeutic landscape. [WATCH TIME: 7 minutes]
The chief executive officer and the chief scientific officer at CureDuchenne talked about a recent webinar that discussed the broad FDA approval of a gene therapy for Duchenne muscular dystrophy, highlighting patient choice and the ongoing efforts to improve treatments. [WATCH TIME: 9 minutes]
